Sanofi and Denali Halt Multiple Sclerosis Study After Oditrasertib Fails to Meet Endpoints

Sanofi has decided to terminate the Phase II trial of oditrasertib, a RIPK1 inhibitor developed with Denali Therapeutics, due to its inability to meet primary and secondary endpoints in the study for multiple sclerosis (MS)[1][2]. Despite targeting the inflammatory RIPK1 protein to reduce neuronal damage, the drug failed to demonstrate significant changes in serum neurofilament light chain levels compared to placebo[1][2]. The discontinuation marks another setback in the Sanofi-Denali partnership, which has faced multiple challenges including previous failures in amyotrophic lateral sclerosis trials earlier this year[1][2].